Tap to enable a layout that focuses on the article.
Advertisement
Business

Amgen Buys Rights From Human Genome

L.A. Times Archives
From Bloomberg News

Amgen Inc. of Thousand Oaks acquired rights from Human Genome Sciences Inc. to develop and sell potential treatments for cancer and immune deficiencies.

A statement by Human Genome didn’t disclose the price. The potential treatments and tests are based on a gene identified by the company.

More to Read

BusinessTechnology & the Internet

Inside the business of entertainment

The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.

By continuing, you agree to our Terms of Service, which include arbitration and a class action waiver. You agree that we and our third-party vendors may collect and use your information, including through cookies, pixels and similar technologies, for the purposes set forth in our Privacy Policy such as personalizing your experience and ads.

More From the Los Angeles Times

Most Read in Business

Advertisement
Advertisement